56580-4 |
Renin^20M post XXX challenge |
CCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Renin [Enzymatic activity/volume] in Plasma --20 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL/h |
|
|
|
|
|
|
CHAL |
|
56580-4 |
|
|
|
|
Observation |
|
|
|
0 |
Renin 20M p chal Plas-cCnc |
|
|
|
N |
|
20M p chal; Active renin; After; Angiotensin forming enzyme; Angiotensinogenase; Cardio; Cardiology; Catalytic Concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Heart Disease; Kidney; Nephrology; p chal; Pl; Plasma; Plasma renin activity; Plsm; Point in time; PRA; PST; QNT; Quan; Quant; Quantitative; Random; Renal |
2.42 |
2.29 |
|
|
|
|
|
|
|
ng/mL/h |
|
|
|
0 |
56581-2 |
Insulin^12M post XXX challenge |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Units/volume] in Serum or Plasma --12 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mIU/mL;uIU/mL |
|
|
|
|
|
|
CHAL |
|
56581-2 |
|
|
|
|
Observation |
|
|
|
0 |
Insulin 12M p chal SerPl-aCnc |
|
|
|
N |
|
12M p chal; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; HUM; Humulin; IH7; Insul; Lente; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente |
2.68 |
2.29 |
|
|
|
|
|
|
|
u[IU]/mL |
|
|
|
0 |
56582-0 |
C peptide^10M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
C peptide [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
56582-0 |
|
|
|
|
Observation |
|
|
|
0 |
C peptide 10M p chal SerPl-mCnc |
|
|
|
N |
|
10M p chal; After; CHEMISTRY.CHALLENGE TESTING; Connecting peptide of insulin; Level; Mass concentration; p chal; Pept; Pl; Plasma; Plsm; Point in time; Pro-insulin c peptide; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
56583-8 |
C peptide^45M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
C peptide [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
56583-8 |
|
|
|
|
Observation |
|
|
|
0 |
C peptide 45M p chal SerPl-mCnc |
|
|
|
N |
|
45M p chal; After; CHEMISTRY.CHALLENGE TESTING; Connecting peptide of insulin; Level; Mass concentration; p chal; Pept; Pl; Plasma; Plsm; Point in time; Pro-insulin c peptide; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
56584-6 |
C peptide^12M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
C peptide [Mass/volume] in Serum or Plasma --12 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
56584-6 |
|
|
|
|
Observation |
|
|
|
0 |
C peptide 12M p chal SerPl-mCnc |
|
|
|
N |
|
12M p chal; After; CHEMISTRY.CHALLENGE TESTING; Connecting peptide of insulin; Level; Mass concentration; p chal; Pept; Pl; Plasma; Plsm; Point in time; Pro-insulin c peptide; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
56585-3 |
Cortisol^45M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pg/mL;ug/dL |
|
|
|
|
|
|
CHAL |
|
56585-3 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 45M p chal SerPl-mCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; 45M p chal; After; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; F; hydrocortisone; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.29 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
56586-1 |
Dehydroepiandrosterone^15M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56586-1 |
|
|
|
|
Observation |
|
|
|
0 |
DHEA 15M p chal SerPl-mCnc |
|
|
|
N |
|
15M p chal; After; CHEMISTRY.CHALLENGE TESTING; DHEA; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Prasterone; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
56587-9 |
Dehydroepiandrosterone^30M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56587-9 |
|
|
|
|
Observation |
|
|
|
0 |
DHEA 30M p chal SerPl-mCnc |
|
|
|
N |
|
30M p chal; After; CHEMISTRY.CHALLENGE TESTING; DHEA; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Prasterone; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
56588-7 |
Dehydroepiandrosterone sulfate^45M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mcg/dL; mcg/mL |
|
|
|
|
|
|
CHAL |
|
56588-7 |
|
|
|
|
Observation |
|
|
|
0 |
DHEA-S 45M p chal SerPl-mCnc |
|
|
|
N |
|
45M p chal; adrenal dysfunction; After; CHEMISTRY.CHALLENGE TESTING; DHEA; DHEAS; DHEA-S; DHEA-SO4; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Prasterone; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SO4; SO4-2; SR; Sulf |
2.4 |
2.29 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
56589-5 |
Dehydroepiandrosterone^1.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56589-5 |
|
|
|
|
Observation |
|
|
|
0 |
DHEA 1.5h p chal SerPl-mCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p chal; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; DHEA; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Prasterone; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
5659-8 |
Gold |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Gold [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
DRUG/TOX |
|
5659-8 |
|
|
|
|
Both |
|
|
|
0 |
Gold SerPl-mCnc |
|
|
|
Y |
|
AU; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
56590-3 |
Dehydroepiandrosterone^2H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --2 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56590-3 |
|
|
|
|
Observation |
|
|
|
0 |
DHEA 2h p chal SerPl-mCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p chal; After; CHEMISTRY.CHALLENGE TESTING; DHEA; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Prasterone; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
56591-1 |
Dehydroepiandrosterone sulfate^3H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --3 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mcg/dL; mcg/mL |
|
|
|
|
|
|
CHAL |
|
56591-1 |
|
|
|
|
Observation |
|
|
|
0 |
DHEA-S 3h p chal SerPl-mCnc |
|
|
|
N |
|
3h p chal; adrenal dysfunction; After; CHEMISTRY.CHALLENGE TESTING; DHEA; DHEAS; DHEA-S; DHEA-SO4; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Prasterone; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SO4; SO4-2; SR; Sulf |
2.4 |
2.29 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
56592-9 |
Follitropin^10M post XXX challenge |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma --10 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
IU/L;mIU/mL |
|
|
|
|
|
|
CHAL |
|
56592-9 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 10M p chal SerPl-aCnc |
|
|
|
N |
|
10M p chal; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.38 |
2.29 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
56593-7 |
Follitropin^3H post XXX challenge |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma --3 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
IU/L;mIU/mL |
|
|
|
|
|
|
CHAL |
|
56593-7 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 3h p chal SerPl-aCnc |
|
|
|
N |
|
3h p chal; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.29 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
56594-5 |
Thyrotropin^3H post XXX challenge |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyrotropin [Units/volume] in Serum or Plasma --3 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mIU/mL;uIU/mL |
|
|
|
|
|
|
CHAL |
|
56594-5 |
|
|
|
|
Observation |
|
|
|
0 |
TSH 3h p chal SerPl-aCnc |
|
|
|
N |
|
3h p chal; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Thyroid stimulating hormone; Thyrotropic hormone; TSH |
2.68 |
2.29 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
56595-2 |
Latex recombinant (rHev b) 3 Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Latex recombinant (rHev b) 3 IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
56595-2 |
|
|
|
|
Both |
|
|
|
0 |
Latex (rHev b) 3 IgE Qn |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Hevea braziliensis; III; Immune globulin E; Immunoglobulin E; k082; k217; k82; Latex (rHev b) 3; Ltx; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.42 |
2.29 |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
56596-0 |
Latex recombinant (rHev b) 5 Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Latex recombinant (rHev b) 5 IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
56596-0 |
|
|
|
|
Both |
|
|
|
0 |
Latex (rHev b) 5 IgE Qn |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Hevea braziliensis; Immune globulin E; Immunoglobulin E; k082; k218; k82; Latex (rHev b) 5; Ltx; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.42 |
2.29 |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
56597-8 |
Latex recombinant (rHev b) 8 Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Latex recombinant (rHev b) 8 IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
56597-8 |
|
|
|
|
Both |
|
|
|
0 |
Latex (rHev b) 8 IgE Qn |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Hevea braziliensis; Immune globulin E; Immunoglobulin E; k082; k221; k82; Latex (rHev b) 8; Ltx; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.42 |
2.29 |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
56598-6 |
Epstein Barr virus early Ab.IgM |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Epstein Barr virus early IgM Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
56598-6 |
|
IA |
|
|
Both |
|
|
|
0 |
EBV EA IgM Ser IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; EA; EBV; EBV EA; EIA; ELFA; ELISA; Enzyme immunoassay; Epstn; HHV-4; human herpesvirus 4; IAA; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Mono; Mononucleosis; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; SUDS; UniversalLabOrders |
2.73 |
2.29 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
56599-4 |
Epstein Barr virus capsid Ab.IgM |
ACnc |
CSF |
Pt |
Qn |
IA |
|
ACTIVE |
Epstein Barr virus capsid IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
56599-4 |
|
IA |
|
|
Both |
|
|
|
0 |
EBV VCA IgM CSF IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; CAP; Cerebral spinal fluid; Cerebrospinal Fl; EBV; EBV capsid Ab; EBV VCA; EIA; ELFA; ELISA; Enzyme immunoassay; Epstn; HHV-4; human herpesvirus 4; IAA; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Mono; Mononucleosis; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS; VCA; Viral capsid |
2.69 |
2.29 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
566-0 |
Cryptosporidium sp Ag |
PrThr |
XXX |
Pt |
Ord |
IF |
|
ACTIVE |
Cryptosporidium sp Ag [Presence] in Specimen by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
566-0 |
|
IF |
|
|
Both |
|
|
|
0 |
Cryptosp Ag Spec Ql IF |
|
|
|
|
|
ACIF; Anticomplement Immunofluorescence; Antigen; Antigens; Crypt; Crypto; Cryptosporidiosis; DFA; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; species; spp; Time Resolved Fluorescence; To be specified in another part of the message; TRF; Unspecified |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
5660-6 |
Gold |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Gold [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
DRUG/TOX |
|
5660-6 |
|
|
|
|
Both |
|
|
|
0 |
Gold Ur-mCnc |
|
|
|
Y |
|
AU; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
56600-0 |
Vespa crabro Ab.IgG |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
European Hornet IgG Ab [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
ALLERGY |
|
56600-0 |
|
|
|
|
Both |
|
|
|
0 |
European Hornet IgG-mCnc |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; European hornet; i75; Immune globulin G; Immunoglobulin G; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
56601-8 |
Hyaluronate |
MCnc |
Periton fld |
Pt |
Qn |
|
|
ACTIVE |
Hyaluronate [Mass/volume] in Peritoneal fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
56601-8 |
|
|
|
|
Both |
|
|
|
0 |
Hyaluronate Prt-mCnc |
|
|
|
N |
|
Ascites; Ascitic fluid; Ascitis; DRUG/TOXICOLOGY; Drugs; HA; Hyaluronan; Hyaluronic acid; Level; Mass concentration; Peritoneal fluid; Point in time; Prt; QNT; Quan; Quant; Quantitative; Random |
2.42 |
2.29 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |